Vismodegib CAS 879085-55-9

Cur síos ar an Táirge:

Ainm Táirge: Vismodegib CAS 879085-55-9

 

Comhchiallaigh:

2-Chloro-N-[4-clóra-3-(2-piridinil)feinil]-4-(meitil-sulfóin)beinsimíd;BROMO-1-NAPHTA

BenzaMide, 2-clóra-N-[4-clóra-3-(2-piridinil)feanil]-4-(Methylsulfonyl)-;

VisModegib (GDC-0449);

 

Airíonna Ceimiceacha & Fisiceacha

Dealramh: Bán go Soladach Lasmuigh den Bhán

Measúnacht: 99%+

Fiuchphointe:561.6±50.0 céim

Leáphointe:179-181 céim

Meáchan Móilíneach: 421.3

Dlús: 1.440

Pka:10.72±0.70

Cobhsaíocht: Cobhsaí ar feadh 2 bhliain ó dháta an cheannaigh mar a sholáthraítear é. Is féidir tuaslagáin in DMSO nó in eatánól a stóráil ag -20 céim ar feadh suas le 3 mhí.

 

Iarratas:

Vimodej targets SMO protein and inhibits Gli activation, thereby inhibiting downstream gene transcription and expression.For the treatment of locally progressive or metastatic basal cell carcinoma in adults who have recurred after surgery or are not well treated with surgery or radiotherapy; One of the most common skin cancers is basal cell carcinoma (BCC), which originates in the surface layer of the skin and does not cause pain to patients. The risk was greatest for skin diseases that were regularly exposed to the sun or ultraviolet light. The development and listing of Vimedji has brought good news to patients with BCC, and its clinical role is important and the target market is huge, and it has to grow into a "giant bomb" class (>$1 billiún) druga amach anseo.

 

 

 

Má tá suim agat inár dtáirgí nó má tá aon cheist agat, bíodh leisce ort teagmháil a dhéanamh linn!

 

 

Déantar táirgí faoi phaitinn a thairiscint chun críche T&F amháin. Mar sin féin, luíonn an fhreagracht deiridh go heisiach ar an gceannaitheoir.

Clibeanna Te: vismodegib cas 879085-55-9, monaróirí, soláthraithe, monarcha, ceannach, i stoc

• 'Nar par ya: Tricine CAS 5704-04-1
• Next2: Trametinib CAS 871700-17-3